Anaphylactic reaction after systemic application of aprotinin triggered by aprotinin-containing fibrin sealant.
We report a 67-yr-old male after multiple surgical procedures for treatment of arterial occlusive disease who suffered an anaphylactic reaction after administration of aprotinin (Trasylol) prior to urgent coronary artery bypass surgery. The patient had been treated with aprotinin-containing fibrin sealant in 2004 and in 2007, 2 wk before coronary artery bypass surgery. The postoperative serologic screening revealed positive results for qualitative aprotinin-specific IgG, highly elevated quantitative aprotinin-specific IgG and moderately elevated aprotinin-specific IgE antibodies.
Kober
Benjamin J
BJ
Division of Thoracic, Cardiac and Vascular Surgery, Tübingen University Hospital, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany.
Scheule
Albertus M
AM
Voth
Vladimir
V
Deschner
Norbert
N
Schmid
Eckhard
E
Ziemer
Gerhard
G
D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced*; D007611:Aprotinin / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001026:Coronary Artery Bypass; D015718:Fibrin Tissue Adhesive / Q000009:adverse effects*; D006490:Hemostatics / Q000009:adverse effects*; D006801:Humans; D008297:Male; D015842:Serine Proteinase Inhibitors / Q000009:adverse effects*
D015718:Fibrin Tissue Adhesive; D006490:Hemostatics; D015842:Serine Proteinase Inhibitors; D007611:Aprotinin